Literature DB >> 10379521

Brain noradrenergic receptors in major depression and schizophrenia.

V Klimek1, G Rajkowska, S N Luker, G Dilley, H Y Meltzer, J C Overholser, C A Stockmeier, G A Ordway.   

Abstract

The binding of [125I]p-iodoclonidine to alpha-2, and/or [125I]iodopindolol to beta-1 and beta-2 adrenoceptors was measured in right prefrontal cortex (Brodmann's area 10) and right hippocampus from subjects with DSM-III-R diagnoses of major depression (n = 15) or schizophrenia (n = 8) as well as from control subjects (n = 20). No significant differences between study groups were observed in binding to alpha-2 adrenoceptors in any of the six layers of prefrontal cortex or in any of the hippocampal fields. Likewise, there were no significant differences in beta-1 or beta-2 adrenoceptor binding in any of the hippocampal fields between control and major depressive subjects. In contrast, binding to beta-1 adrenoceptors, but not beta-2 adrenoceptors, was significantly lower (-13 to -27%) in most hippocampal fields of schizophrenic subjects as compared to control subjects or to major depressives. Alterations in beta-1 adrenoceptor binding in the hippocampus of schizophrenics provide further evidence for a role of central noradrenergic neurons in the neurochemical pathology of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10379521     DOI: 10.1016/S0893-133X(98)00134-1

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  16 in total

Review 1.  Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?

Authors:  L Dépatie; S Lal
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

Review 2.  Targeting the hippocampal mossy fiber synapse for the treatment of psychiatric disorders.

Authors:  Katsunori Kobayashi
Journal:  Mol Neurobiol       Date:  2009-01-08       Impact factor: 5.590

3.  Power spectrum scale invariance identifies prefrontal dysregulation in paranoid schizophrenia.

Authors:  Anca R Radulescu; Denis Rubin; Helmut H Strey; Lilianne R Mujica-Parodi
Journal:  Hum Brain Mapp       Date:  2011-05-12       Impact factor: 5.038

Review 4.  A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction.

Authors:  R L Bell; S Hauser; Z A Rodd; T Liang; Y Sari; J McClintick; S Rahman; E A Engleman
Journal:  Int Rev Neurobiol       Date:  2016-03-21       Impact factor: 3.230

5.  The N251K functional polymorphism in the alpha(2A)-adrenoceptor gene is not associated with depression: a study in suicide completers.

Authors:  Idoia Martín-Guerrero; Luis F Callado; Koldo Saitua; Guadalupe Rivero; Africa García-Orad; J Javier Meana
Journal:  Psychopharmacology (Berl)       Date:  2005-12-07       Impact factor: 4.530

6.  Association of regulatory variants of dopamine β-hydroxylase with cognition and tardive dyskinesia in schizophrenia subjects.

Authors:  Toyanji J Punchaichira; Anirban Mukhopadhyay; Prachi Kukshal; Triptish Bhatia; Smita N Deshpande; B K Thelma
Journal:  J Psychopharmacol       Date:  2020-01-08       Impact factor: 4.153

7.  Differential modulation of α-1 adrenoceptor subtypes by antidepressants in the rat brain.

Authors:  D Ramakrishna; M N Subhash
Journal:  J Neural Transm (Vienna)       Date:  2010-12-07       Impact factor: 3.575

8.  Modulation of Monoaminergic Systems by Antidepressants in the Frontal Cortex of Rats After Chronic Mild Stress Exposure.

Authors:  David Martín-Hernández; Marta P Pereira; Hiram Tendilla-Beltrán; José L M Madrigal; Borja García-Bueno; Juan C Leza; Javier R Caso
Journal:  Mol Neurobiol       Date:  2019-05-03       Impact factor: 5.590

Review 9.  α2 adrenergic receptor dysregulation in depressive disorders: implications for the neurobiology of depression and antidepressant therapy.

Authors:  Christopher Cottingham; Qin Wang
Journal:  Neurosci Biobehav Rev       Date:  2012-08-13       Impact factor: 8.989

10.  Heterotrimeric g proteins: insights into the neurobiology of mood disorders.

Authors:  Javier González-Maeso; J Javier Meana
Journal:  Curr Neuropharmacol       Date:  2006-04       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.